J&J Takes $2.58bn Option to Buy in Vivo CAR-T Firm Sail

J&J nabs option to buy ‘in vivo’ CAR-T maker Sail for nearly $2.6B

The deal with the buzzy Flagship Pioneering-backed startup makes J&J the latest large drugmaker to bet that the technology might be able to treat autoimmune conditions.

J&J takes $2.58bn option to buy in vivo CAR-T firm Sail

Johnson & Johnson has bid for a slice of the in vivo CAR-T category, signing an alliance with Sail Bio that could evolve into a $2.58bn takeover.

Johnson & Johnson Announces Collaboration with Sail Biomedicines to Advance in vivo CAR-T Programs and Transform Autoimmune Disease Through Immune Reset

Advances differentiated immunology program with the potential to address significant unmet need in immune-mediated

J&J lines up $2.58B option to buy Sail, Flagship's in vivo CAR-T biotech

The in vivo CAR-T space is getting more competitive as one of the biggest cell therapy players expands its role. Johnson & Johnson is paying $785 million upfront to work with Flagship Pioneering's Sail Biomedicines ...